MR-guided adaptive radiotherapy for advanced lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of magnetic resonance-guided online adaptive radiotherapy (ART) for patients with locally advanced non-small cell lung cancer (LA-NSCLC). The study aims to demonstrate the feasibility of this innovative technique, which allows for personalized treatment by adapting radiation delivery based on real-time changes in tumor geometry and surrounding organs at risk. By optimizing the balance between effective tumor targeting and minimizing toxicity, the trial seeks to improve local tumor control and patient outcomes. The findings will inform the design of a subsequent phase I/II study comparing MR-guided ART to traditional CT-based approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically-proven non-small cell lung cancer (NSCLC)
* Stage III A - C according to the 8th edition of the Union for International Cancer Control (UICC) TNM classification
* Indication for definitive thoracic chemoradiotherapy
* Age ≥ 18 years
* ECOG 0 - 2
* Adequate pulmonary function for chemoradiotherapy confirmed by a current pulmonary function test (≤ 6 weeks from treatment start)
* Ability to lie still on the MR-linac table for at least one hour
* Ability to hold one's breath for at least 20 seconds
* Successful completion of an MR-guided treatment simulation
* For women with childbearing potential: adequate contraception
* Ability of the patient to understand character and individual consequences of the clinical trial
* Written informed consent (must be available before enrolment in the trial)

Exclusion Criteria:

* Involvement of supraclavicular lymph nodes (supraclavicular N3)
* Additional pulmonary lesions (T3 - 4 due to additional lesion in the same or another lobe)
* Previous radiotherapy of the lung and mediastinum, if previous and current target volumes overlap
* Patients who have not yet recovered from acute toxicities of prior therapies
* Contraindications against performing MRI scans (e.g. pacemakers or other implants making MRI impossible)
* Pregnant or lactating women
* Participation in another competing clinical study or observation period of competing trials
* Refusal of the patients to take part in the study

Where it's running

• Universitätsklinikum Tübingen
  Tübingen, Baden-Württemberg, Germany Recruiting
• Ludwig-Maximilian-Universität München
  Münich, Bayern, Germany Recruiting
• University Hospital of Heidelberg, Radiation Oncology
  Heidelberg, Germany Recruiting

Study contacts

• Principal investigator: Juergen Debus, Prof — University Hospital Heidelberg
• Study coordinator: Sebastian Regnery, MD
• Email: sebastian.regnery@med.uni-heidelberg.de
• Phone: +496221 56

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery

  This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07837739

• HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC

  This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Wuhan, Hubei · NCT07824882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.